Metropolis Healthcare buys Core Diagnostics, enhances its cancer testing footprint

Metropolis will acquire 100 per cent stake in Core Diagnostics through a combination of cash and stock, financing 55 per cent of the transaction in cash and 45 per cent through an equity swap, said Ameera Shah, Metropolis Promoter and Executive Chairperson.